Curtis C. Harris, M.D.
Laboratory of Human Carcinogenesis
Building 37, Room 3068A
Bethesda, MD 20892
Our continuing research projects utilize a Precision Medicine strategy . As described in the overview of LHC, our strategy and strength is to conduct laboratory-epidemiological investigations and to mentor young investigators.
Project 1: Biomarkers in Cancer Diagnosis, Prognosis, and Therapeutic Outcome. Biologically relevant biomarkers may help guide therapeutic decisions for cancer patients. Chronic inflammation and infection are major causes of cancer. Key mediators of inflammation-induced cancer include nuclear factor kappa B, reactive oxygen and nitrogen species, inflammatory cytokines, prostaglandins and specific microRNAs (miRNAs). The collective activity of these mediators is largely responsible for either a pro-tumorigenic or anti-tumorigenic inflammatory response through changes in cell proliferation, cell death, cellular senescence, DNA mutation rates, DNA methylation and angiogenesis. These studies require multiple cohorts to conduct ethnic, racial or geographic analyses including biological factors of health disparity, e.g., Norway Lung Cancer Cohort (A. Haugen), Japanese Lung Cancer Cohort (J. Yokota), German Colon Cancer Cohort (M. Mohler), Japanese Colon Cancer Cohort (W. Yasui), Hong Kong Colon Cancer Cohort (S.Y. Leung), and prospective MD Anderson Colon Cancer Cohort (S. Kopetz) and a prospective Southern Community Lung Cancer Cohort (Bill Blot). We are investigating connections between inflammation, miRNAs, metabolomics, microbiome, and cancer; highlighting how our improved understanding of these connections may provide novel preventive, diagnostic, prognostic, and therapeutic strategies to reduce the health burden of cancer. Thus our program strongly emphasizes molecular mechanisms of miRNAs and cytokines and their association with human cancer diagnosis, prognosis, and therapeutic outcomes.
A continuing aim of our research is to identify diagnostic, prognostic and predictive therapeutic biomarkers that can provide actionable information to guide medical decisions for cancer patients. We and our collaborators have a strong publication history in the field of cancer biomarkers. We continue to build on this foundation and contribute to the international effort by both translational and clinical cancer researchers. Of critical importance is the development of diagnostic biomarkers to identify individuals with early stage cancer or those at high risk of developing cancer. Prognostic biomarkers that can guide therapeutic decisions, especially in early stage patients, are equally important.
Over the last four years, we have been successful at publishing biomarker-related manuscripts in lung, colon and esophageal cancer. These studies use a variety of techniques to examine the profiles of miRNAs and inflammation genes and metabolotic analysis as they relate to cancer diagnosis, prognosis and/or therapeutic outcome. In our studies, we routinely begin by using tissues from cancer patients recruited through the NCI-MD resource contract and we then validate relevant findings in independent cohorts from various regions of the world. Our strategy is aimed at finding associations that are generalizable to cancer populations globally and not limited to one study population. Our goals are in line with the research objectives of "Improving Early Detection and Diagnosis" and "Understanding the Mechanisms of Cancer" as laid out in the 2013 NCI Congressional Budget Justification.
Over the next four years we continue to use next-generation omics-based approaches to identify molecular characteristics of early stage cancer that are responsible for aggressive disease. This includes using metabolomic strategies to determine if blood and urine-based metabolites are diagnostic and prognostic biomarkers for lung cancer and begin studies examining the microbiome and how it can affect prognosis and therapeutic outcomes of colon cancer.
Project 2: Integrative Molecular Epidemiology of Human Cancer. Gene-environment interaction is a seminal concept in the integrative molecular epidemiology of human cancer. Our ongoing case-control studies (using population-based controls) focus on lung cancer, a tobacco-related cancer, and colon cancer, a cancer type more associated with chronic inflammation. These studies require the integration of data from genome associated studies, analyses of carcinogen exposure, rapidly developing technologies, bioinformatics, social-ethical concerns, and epidemiological study-design methods. Moreover, they integrate the hypothesis, aims, and demographic characteristics of study subjects from multiple investigations. We also validate our results with independent cohorts, e.g., the prospective Southern Community Cohort Study and Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, and Mayo Clinic Never Smoker Lung Cancer Cohort. We have a long standing interest and record of accomplishments of health disparities studies including African American (AA) and European American (EA) cohorts. We are currently finishing the analysis of a Genome Wide Association Study (GWAS) of AA Lung Cancer Cases. Functional studies of these single nucleotide polymorphisms (SNPs) in coding and non-coding genes that are uniquely associated with AAs have been initiated.
We and our collaborators have been longtime contributors to the field of molecular epidemiology. Our continuing research projects complement the research objectives of "Improving Early Detection and Diagnosis" and "Understanding the Mechanisms of Cancer" as laid out in the 2013 NCI Congressional Budget Justification and NCI's research priorities to improve early detection and prognosis and to understand the causes of cancer. We have focused on an integrative epidemiological approach to our studies. This has meant the inclusion of new high-throughput platforms for genotyping, such as SequenomTM and FluidigmTM (TaqMan), and omics platforms such as NanostringTM and methylation arrays. We have leveraged the expansive design of the case-control study resource to integrate molecular and biological data into our epidemiological studies. Moreover, with an appreciation for the power that large-scale collaborative studies can provide, we have contributed to several national and international consortia to create a genomic map of recombination in AA and explore the contribution of genetic mosaicism to cancer. We have participated with our colleagues in the International Lung Cancer Consortium in several pooled epidemiological analyses, including one to assess the contribution of family history to lung cancer. Recently, we conceived, and are leading, a multi-center study to explore the genetic and biological basis of racial health disparity through the first GWAS of lung cancer in AA. We are also incorporating Ancestry Informative Markers (AIM) to control for confounding by population admixture.
Project 3: p53, Aging and Cancer. The p53 network is an intrinsic monitoring and responsive pathway of telomeric attrition involved in cellular aging and senescence. Cellular senescence is a tumor suppressive mechanism that can be activated by p53 in cancer cells. We are currently studying the molecular mechanisms of cellular senescence in normal human cells and the role of the telometric multiprotein complex, shelterin, that includes TRF2 in aging and carcinogenesis; David Lane, Ettore Appella and Thomas Zheng are collaborators. Our research focuses on integrative p53 and miRNA networks in tumor suppression and the functional role of p53 isoforms, e.g., "dominant negative" delta133p53 and "co-transactivator" of p53, p53beta, both as natural regulators of cellular senescence and stem cell biology and their dysregulation in cancer.
p53 regulates cellular stress responses, including cellular senescence, which functions as a tumor suppressor mechanism in vivo and may contribute to organismal aging in humans. Natural p53 protein isoforms are produced via alternative splicing (e.g., p53beta isoform) or usage of alternative promoters (e.g., delta133p53 isoform) and may be degraded via an isoform-specific protein turnover mechanism, i.e., selective autophagy. These p53 isoforms likely play physiological roles in p53-regulated cellular senescence in vivo during carcinogenesis and aging. The p53-mediated regulation of pluripotent stem cells, such as human embryonic stem cells (hESC) and induced pluripotent stem cells (iPSC), normal tissue stem cells and cancer stem cells may also be modulated by these p53 isoforms.
Haznadar M, Cai Q, Krausz KW, Bowman ED, Margono E, Noro R, Thompson MD, Mathé EA, Munro HM, Steinwandel MD, Gonzalez FJ, Blot WJ, Harris CC. Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 2016;25(6):978-86.
Turnquist C, Horikawa I, Foran E, Major EO, Vojtesek B, Lane DP, Lu X, Harris BT, Harris CC. p53 isoforms regulate astrocyte-mediated neuroprotection and neurodegeneration. Cell Death Differ. 2016;23(9):1515-28.
Mathé EA, Patterson AD, Haznadar M, Manna SK, Krausz KW, Bowman ED, Shields PG, Idle JR, Smith PB, Anami K, Kazandjian DG, Hatzakis E, Gonzalez FJ, Harris CC. Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res. 2014;74(12):3259-70.
Akagi I, Okayama H, Schetter AJ, Robles AI, Kohno T, Bowman ED, Kazandjian D, Welsh JA, Oue N, Saito M, Miyashita M, Uchida E, Takizawa T, Takenoshita S, Skaug V, Mollerup S, Haugen A, Yokota J, Harris CC. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res. 2013;73(13):3821-32.
Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, Mazur SJ, Appella E, Vojtesek B, Blasco MA, Lane DP, Harris CC. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest. 2013;123(12):5247-57.
Related Scientific Focus Areas
Genetics and Genomics
This page was last updated on June 15th, 2017